Cargando…

A Promising New Therapy of Oral Ixazomib Without Rituximab for Waldenstrom Macroglobulinemia

Detalles Bibliográficos
Autores principales:	Ma, Wanlu, Zhao, Jiawei, Zhang, Lu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Galenos Publishing 2021
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927456/ https://www.ncbi.nlm.nih.gov/pubmed/33121225 http://dx.doi.org/10.4274/tjh.galenos.2020.2020.0521

Ejemplares similares

Interstitial pneumonitis related to rituximab therapy for Waldenström's macroglobulinemia
por: Bai, Xueyan, et al.
Publicado: (2015)

Rituximab and Fludarabine or Cyclophosphamide Combination Treatment for Older Waldenström Macroglobulinemia Patients
por: Xu, XiaoWei, et al.
Publicado: (2013)

Pseudohyperphosphatemia in Waldenstrom's Macroglobulinemia
por: Amalnath, S. D., et al.
Publicado: (2013)

Successful Treatment of Rituximab-Refractory Waldenstrom Macroglobulinemia-Related Kidney Damage With Bruton Tyrosine Kinase Inhibitor
por: Nie, Guangyan, et al.
Publicado: (2021)

Ibrutinib-Induced Pancreatitis in Patients with Waldenstrom Macroglobulinemia
por: Büyükkurt, Nurhilal, et al.
Publicado: (2023)

What is the most appropriate regimen for untreated Waldenström macroglobulinemia? - An updated analysis of rituximab and half-dose CHOP therapy and cost effectiveness
por: Sekiguchi, Naohiro, et al.
Publicado: (2019)

Waldenstrom's macroglobulinemia presenting with lytic bone lesions: a rare presentation
por: Pujani, Mukta, et al.
Publicado: (2013)

Light chain amyloidosis associated with Waldenström macroglobulinemia: treatment and survival outcomes
por: Gustine, Joshua N., et al.
Publicado: (2022)

Durable response of therapy-related MDS/AML with concomitant Waldenström’s macroglobulinemia treated with venetoclax and azacitidine
por: Hirano, Mitsuhito, et al.
Publicado: (2022)

Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study
por: Kersten, Marie José, et al.
Publicado: (2022)

A case of acquired angioedema associated with Waldenstrom’s macroglobulinemia treated with rituximab
por: Rizk, Caroline, et al.
Publicado: (2014)

Morphea associated with primary biliary cirrhosis and Waldenstrom macroglobulinemia: Response to rituximab
por: Traboulsi, Danya, et al.
Publicado: (2018)

Inflammation in Waldenström macroglobulinemia is associated with 6q deletion and need for treatment initiation
por: Forgeard, Nathalie, et al.
Publicado: (2022)

Successful Management of Ibrutinib-Induced Thrombocytopenia with Eltrombopag in a Patient with Waldenström Macroglobulinemia
por: Erçalışkan, Abdülkadir, et al.
Publicado: (2022)

Waldenstrom’s Macroglobulinemia: An Update
por: Mazzucchelli, Maddalena, et al.
Publicado: (2018)

Diagnostics in Waldenström’s macroglobulinemia: a consensus statement of the European Consortium for Waldenström’s Macroglobulinemia
por: Dogliotti, Irene, et al.
Publicado: (2022)

Waldenström macroglobulinemia: biology, genetics, and therapy
por: Paludo, Jonas, et al.
Publicado: (2016)

New developments in the management of Waldenström macroglobulinemia
por: Abeykoon, Jithma P, et al.
Publicado: (2017)

PB2074: IBRUTINIB AS A PROMISING TREATMENT FOR WALDENSTRÖM MACROGLOBULINEMIA
por: Ilhan, O., et al.
Publicado: (2022)

Rituximab-based combination therapy in patients with Waldenström macroglobulinemia: a systematic review and meta-analysis
por: Zheng, Yan-Hua, et al.
Publicado: (2019)

Lymphoplasmacytic non-Hodgkin lymphoma/Waldenström's macroglobulinemia with CD5+, CD23+, and CD10-
por: D'Angelo, Guido, et al.
Publicado: (2013)

P1105: FINAL RESULTS OF THE PHASE I/II HOVON124/ECWM-R2 STUDY INCLUDING 2-YEAR RITUXIMAB MAINTENANCE AFTER INDUCTION WITH IXAZOMIB, RITUXIMAB AND DEXAMETHASONE IN RELAPSED WALDENSTRÖM’S MACROGLOBULINEMIA
por: Dimopoulos, M.-A., et al.
Publicado: (2022)

Waldenstrom's macroglobulinemia associated with eosinophilia
por: You, Eunkyoung, et al.
Publicado: (2013)

How to manage Waldenstrom's macroglobulinemia
por: Buske, C, et al.
Publicado: (2013)

Waldenstrom macroglobulinemia: prognosis and management
por: Oza, A, et al.
Publicado: (2016)

Waldenstrom macroglobulinemia: prognosis and management
por: Oza, A, et al.
Publicado: (2015)

Cutaneous macroglobulinosis with Waldenström macroglobulinemia
por: Hassab-El-Naby, Hussein M.M., et al.
Publicado: (2020)

Genomic landscape of Waldenström's macroglobulinemia
por: Treon, Steven P., et al.
Publicado: (2019)

Bone localization of Waldenstrom’s macroglobulinemia
por: Daste, Camille, et al.
Publicado: (2023)

Monoclonal antibody-based therapies for Waldenström's macroglobulinemia
por: Fotiou, Despina, et al.
Publicado: (2022)

Light chain proteinuria revealing mu-heavy chain disease: an atypical presentation of Waldenström macroglobulinemia in two cases
por: Vergneault, Hélène, et al.
Publicado: (2021)

A Focus on Waldenström Macroglobulinemia and AL Amyloidosis
por: Lu, Rebecca, et al.
Publicado: (2022)

Treatment paradigm in Waldenström macroglobulinemia: frontline therapy and beyond
por: Zanwar, Saurabh, et al.
Publicado: (2022)

Waldenström Macroglobulinemia: Mechanisms of Disease Progression and Current Therapies
por: Boutilier, Ava J., et al.
Publicado: (2022)

Pseudovitelliform Subfoveal Deposit in Waldenström's Macroglobulinemia
por: Brolly, Aurélie, et al.
Publicado: (2012)

Splenic re-irradiation for waldenstrőm’s macroglobulinemia
por: Wei, Zhou, et al.
Publicado: (2012)

Membranoproliferative glomerulonephritis complicating Waldenström’s macroglobulinemia
por: Kratochvil, David, et al.
Publicado: (2012)

Clinical Features of Waldenstrom Macroglobulinemia in Korea
por: Bang, Soo-Mee, et al.
Publicado: (2004)

CNS Vasculitis Associated with Waldenström Macroglobulinemia
por: Riangwiwat, Tanawan, et al.
Publicado: (2016)

Waldenström macroglobulinemia treatment algorithm 2018
por: Gertz, Morie A.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_msld5jsil5i0bbo4bq3kh8jjtq